Zacks Investment Research on MSN
Will ANIP's rare disease franchise maintain momentum in 2026?
ANI Pharmaceuticals’ ANIP rare disease franchise spearheaded its growth in 2025. This robust growth was fueled by the strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback